A regulatory requirement non interventional study to monitor the safety and effectiveness of JARDIANCE® (empagliflozin 10mg, 25mg) in Korean patients with type 2 diabetes mellitus (JARDIANCE® rPMS in Korean patients with T2DM)

First published 31/05/2016

Last updated 18/12/2025

EU PAS number:

EUPAS13627

Study

Finalised

Documents

Study protocol

Updated protocol

1245-0116_Protocol_SAP_redacted.pdf

First published: 09/12/2025

English (574.63 KB - PDF) View document

Study results

1245-0116_Synopsis.pdf

English (458.09 KB - PDF) View document

Study report

Other information

Secondary tabs